目的 探討達格列凈片聯(lián)合普伐他汀鈉片治療慢性心力衰竭的臨床療效。方法 選取邢臺市中心醫(yī)院在2022年2月—2023年12月收治的144例慢性心力衰竭患者，根據(jù)隨機數(shù)字表法將所有患者分為對照組和治療組，每組各72例。對照組口服普伐他汀鈉片，2片/次，1次/d。治療組在對照組基礎(chǔ)上口服達格列凈片，1片/次，1次/d。兩組患者連續(xù)治療2個月。比較兩組的臨床療效、病情程度、生活質(zhì)量、心功能和血清指標。結(jié)果 治療后，與對照組總有效率83.33%比較，治療組的總有效率94.44%更高，組間差異顯著（P＜0.05）。治療后，兩組的心衰評分、明尼蘇達心力衰竭生活質(zhì)量量表（MLHFQ）評分均明顯降低（P＜0.05）；治療組的心衰評分、MLHFQ評分低于對照組（P＜0.05）。治療后，兩組的左室射血分數(shù)（EF）顯著升高，左心室重塑指數(shù)（LVRI）、左心室質(zhì)量指數(shù)（LVMI）顯著降低（P＜0.05）；治療組的EF高于對照組，LVRI、LVMI低于對照組（P＜0.05）。治療后，兩組的血清N端腦鈉肽前體（NT-proBNP）、視黃醇結(jié)合蛋白4（RBP4）、脂聯(lián)素（ADP）水平顯著降低（P＜0.05）；與對照組比較，治療組的血清NT-proBNP、RBP4、ADP更低（P＜0.05）。結(jié)論 達格列凈片聯(lián)合普伐他汀鈉片可提高慢性心力衰竭的治療效果，顯著減輕病情嚴重程度，改善患者生活質(zhì)量和心功能，降低心肌損傷。

Objective To investigate the clinical efficacy of Dapagliflozin Tablets combined with Pravastatin Sodium Tablets in treatment of chronic heart failure. Methods Patients (114 cases) with chronic heart failure in Xingtai Central Hospital from February 2022 to December 2023 were divided into control and treatment groups according to the random number method, and each group had 72 cases. Patients in the control group were po administered with Pravastatin Sodium Tablets, 2 tablets/time, once daily. Patients in the treatment group were po administered with Dapagliflozin Tablets on the basis of the control group, 1 tablets/time, once daily. Patients in two groups were treated for 2 months. The clinical efficacies, the degree of illness, the quality of life, the heart function, and the serum indicators in two groups were compared. Results After treatment, the total effective rate of the treatment group was 94.44%, which was higher than 83.33% of the control group, and the difference between groups was significant (P < 0.05). After treatment, the heart failure score and MLHFQ score of two groups were significantly decreased (P < 0.05), and the scores of heart failure and MLHFQ in the treatment group were lower than those in the control group (P< 0.05). After treatment, EF in two groups was significantly increased, but LVRI and LVMI in two groups were significantly decreased (P < 0.05). After treatment, EF in treatment group was higher than that in control group, but LVRI and LVMI in treatment group were lower than that in control group (P< 0.05). After treatment, the serum levels of NT-proBNP, RBP4, and ADP in two groups were significantly decreased (P < 0.05). Compared with the control group, the serum levels of NT-proBNP, RBP4, and ADP in the treatment group were lower (P < 0.05). Conclusion Dapagliflozin Tablets combined with Pravastatin Sodium Tablets can significantly reduce the severity of chronic heart failure, improve the quality of life and cardiac function of patients, and reduce myocardial damage.

R972